Targeting the telosome: Therapeutic implications

Marco Folini, Paolo Gandellini, Nadia Zaffaroni

Research output: Contribution to journalArticle

Abstract

Since telomere integrity is required to guarantee the unlimited replicative potential of cancer cells, telomerase, the enzyme responsible for telomere length maintenance in most human tumors, and lately also telomeres themselves have become extremely attractive targets for new anticancer interventions. At the current status of knowledge, it is still not possible to define the best therapeutic target between telomerase and telomeres. It is noteworthy that interfering with telomeres, through direct targeting of telomeric DNA or proteins involved in the telosome complex, could negatively affect the proliferative potential not only of tumors expressing telomerase activity but also of those that maintain their telomeres through alternative lengthening or still unknown mechanisms. This review presents the different therapeutic approaches proposed thus far and developed in preclinical tumor models and discusses the perspectives for their use in the clinical setting.

Original languageEnglish
Pages (from-to)309-316
Number of pages8
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1792
Issue number4
DOIs
Publication statusPublished - Apr 2009

Fingerprint

Telomere
Telomerase
Neoplasms
Telomere Homeostasis
Therapeutics
DNA
Enzymes
Proteins

Keywords

  • Cancer
  • G-quadruplex
  • Telomerase
  • Telomere
  • Telosome

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Cite this

Targeting the telosome : Therapeutic implications. / Folini, Marco; Gandellini, Paolo; Zaffaroni, Nadia.

In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1792, No. 4, 04.2009, p. 309-316.

Research output: Contribution to journalArticle

@article{7af516f1723b4b63bfaef68dde896ada,
title = "Targeting the telosome: Therapeutic implications",
abstract = "Since telomere integrity is required to guarantee the unlimited replicative potential of cancer cells, telomerase, the enzyme responsible for telomere length maintenance in most human tumors, and lately also telomeres themselves have become extremely attractive targets for new anticancer interventions. At the current status of knowledge, it is still not possible to define the best therapeutic target between telomerase and telomeres. It is noteworthy that interfering with telomeres, through direct targeting of telomeric DNA or proteins involved in the telosome complex, could negatively affect the proliferative potential not only of tumors expressing telomerase activity but also of those that maintain their telomeres through alternative lengthening or still unknown mechanisms. This review presents the different therapeutic approaches proposed thus far and developed in preclinical tumor models and discusses the perspectives for their use in the clinical setting.",
keywords = "Cancer, G-quadruplex, Telomerase, Telomere, Telosome",
author = "Marco Folini and Paolo Gandellini and Nadia Zaffaroni",
year = "2009",
month = "4",
doi = "10.1016/j.bbadis.2009.01.014",
language = "English",
volume = "1792",
pages = "309--316",
journal = "Biochimica et Biophysica Acta - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Targeting the telosome

T2 - Therapeutic implications

AU - Folini, Marco

AU - Gandellini, Paolo

AU - Zaffaroni, Nadia

PY - 2009/4

Y1 - 2009/4

N2 - Since telomere integrity is required to guarantee the unlimited replicative potential of cancer cells, telomerase, the enzyme responsible for telomere length maintenance in most human tumors, and lately also telomeres themselves have become extremely attractive targets for new anticancer interventions. At the current status of knowledge, it is still not possible to define the best therapeutic target between telomerase and telomeres. It is noteworthy that interfering with telomeres, through direct targeting of telomeric DNA or proteins involved in the telosome complex, could negatively affect the proliferative potential not only of tumors expressing telomerase activity but also of those that maintain their telomeres through alternative lengthening or still unknown mechanisms. This review presents the different therapeutic approaches proposed thus far and developed in preclinical tumor models and discusses the perspectives for their use in the clinical setting.

AB - Since telomere integrity is required to guarantee the unlimited replicative potential of cancer cells, telomerase, the enzyme responsible for telomere length maintenance in most human tumors, and lately also telomeres themselves have become extremely attractive targets for new anticancer interventions. At the current status of knowledge, it is still not possible to define the best therapeutic target between telomerase and telomeres. It is noteworthy that interfering with telomeres, through direct targeting of telomeric DNA or proteins involved in the telosome complex, could negatively affect the proliferative potential not only of tumors expressing telomerase activity but also of those that maintain their telomeres through alternative lengthening or still unknown mechanisms. This review presents the different therapeutic approaches proposed thus far and developed in preclinical tumor models and discusses the perspectives for their use in the clinical setting.

KW - Cancer

KW - G-quadruplex

KW - Telomerase

KW - Telomere

KW - Telosome

UR - http://www.scopus.com/inward/record.url?scp=64249083673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249083673&partnerID=8YFLogxK

U2 - 10.1016/j.bbadis.2009.01.014

DO - 10.1016/j.bbadis.2009.01.014

M3 - Article

C2 - 19419699

AN - SCOPUS:64249083673

VL - 1792

SP - 309

EP - 316

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 4

ER -